Home » Stocks » BDTX

Black Diamond Therapeutics, Inc. (BDTX)

Stock Price: $26.56 USD -1.29 (-4.63%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $26.92 +0.36 (1.37%) May 13, 4:11 PM
Market Cap 978.19M
Revenue (ttm) n/a
Net Income (ttm) -85.41M
Shares Out 36.16M
EPS (ttm) -13.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $26.56
Previous Close $27.85
Change ($) -1.29
Change (%) -4.63%
Day's Open 27.68
Day's Range 26.17 - 28.11
Day's Volume 368,926
52-Week Range 21.04 - 46.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass. and NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small m...

6 days ago - GlobeNewsWire

Initial pharmacokinetic (PK), safety, and preliminary efficacy data from Phase 1 dose-escalation portion of MasterKey-01 clinical trial to be presented

2 weeks ago - GlobeNewsWire

CAMBRIDGE, Mass. and NEW YORK, April 10, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass. and NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass. and NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small ...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small ...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and NEW YORK, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small ...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small ...

4 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small ...

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) --  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small...

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small ...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small ...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and NEW YORK, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small ...

6 months ago - GlobeNewsWire

Black Diamond is an innovative cancer drug-developer using genetic sequencing to identify families of allosteric mutations, and developing drug molecules to inhibit their proliferation. The company rais...

6 months ago - Seeking Alpha

CAMBRIDGE, Mass. and NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small ...

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of sma...

7 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of sma...

8 months ago - GlobeNewsWire

Dr. Humphrey brings more than 20 years of experience as a leader in oncology drug development Dr. Humphrey brings more than 20 years of experience as a leader in oncology drug development

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and NEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of smal...

9 months ago - GlobeNewsWire

Black Diamond Therapeutics (BDTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

9 months ago - Zacks Investment Research

CAMBRIDGE, Mass. and NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of smal...

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of smal...

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of smal...

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass. and NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of smal...

10 months ago - GlobeNewsWire

Black Diamond Therapeutics (BDTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

CAMBRIDGE, Mass. and NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small...

1 year ago - GlobeNewsWire

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: NERV, SPT, THMO, ZYXI
1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Black Diamond Therapeutics, Inc. (BDTX).

1 year ago - Zacks Investment Research

These four companies just made their debuts. Should they be on your radar?

Other stocks mentioned: ONEM, REYN, ARQT
1 year ago - The Motley Fool

CAMBRIDGE, Mass. and NEW YORK, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of smal...

1 year ago - GlobeNewsWire

Black Diamond Therapeutics (NASDAQ: BDTX) made its public debut Thursday morning, opening at $33 after being priced at $19 per share.

1 year ago - Benzinga

About BDTX

Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an irreversible small molecule inhibitor that is designed to block the function of family of oncogenic proteins defined by driver mutations across a range of tumor types, and which affect the epidermal growth factor receptor (EGFR), the tyrosine-protein kinase, or human epidermal growth factor receptor 2. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mu... [Read more...]

Industry
Biotechnology
IPO Date
Jan 30, 2020
Stock Exchange
NASDAQ
Ticker Symbol
BDTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for BDTX stock is "Strong Buy." The 12-month stock price forecast is 51.60, which is an increase of 94.28% from the latest price.

Price Target
$51.60
(94.28% upside)
Analyst Consensus: Strong Buy